Phase I Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 With Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer
Summary
This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Patients will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumor.
General Information
NCT#: NCT04193904
Study ID: MRx0518-I-003
Trial Phase: Phase I
Trial Sponsor: 4D Pharma PLC
Therapies Used in This Trial: Hypofractionated radiation therapy, MRx0518